Is Sacituzumab govitecan on the market?

Sacituzumab govitecan) was approved by the U.S. Food and Drug Administration (FDA) in April 2020. It was developed and produced by Immunomedics and triple-negative breast cancer (mTNBC) who have received two or more prior therapies. As a targeted cytotoxic agent, it is expected to provide similar efficacy while reducing side effects.

In November 2021 and July 2023, gosatuzumab was also approved by the European Medicines Agency (EMA) and Health Canada respectively. In 2022, it was also approved by the National Medical Products Administration and will be launched in China. In February 2023, the FDA approved gosatuzumab for patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies.

The original gosatuzumab drug marketed in China has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.